Bernstein SocGen Group has increased its price target for HCA Healthcare Inc (NYSE:HCA) to $541.00 from $503.00, while maintaining a Market Perform rating. This adjustment reflects HCA’s strong margin efficiency, robust share buyback capacity, and improved EBITDA forecasts for the next five years. Despite the raised target, Bernstein expressed concerns about the stock’s valuation being at the higher end of its long-term range and potential headwinds to EBITDA growth from moderating rate increases and stabilizing compensation ratios.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
HCA Healthcare stock price target raised to $541 from $503 at Bernstein
Bernstein SocGen Group has increased its price target for HCA Healthcare Inc (NYSE:HCA) to $541.00 from $503.00, while maintaining a Market Perform rating. This adjustment reflects HCA’s strong margin efficiency, robust share buyback capacity, and improved EBITDA forecasts for the next five years. Despite the raised target, Bernstein expressed concerns about the stock’s valuation being at the higher end of its long-term range and potential headwinds to EBITDA growth from moderating rate increases and stabilizing compensation ratios.